Radiopharm Theranostics RADX
NASDAQ RADX
$2.15 +0.09 (+4.36%)
As of: Sep 10, 2026 · 10:29 AM EDT

Radiopharm Theranostics Ltd (RADX) Cost of Revenue (2024 - 2026)

Radiopharm Theranostics' (RADX) quarterly Cost of Revenue came in at $335000.6 in Q2 2026, down 90.68% year-over-year from $3.6 million in Q2 2025, and down 90.68% quarter-over-quarter from $3.6 million in Q2 2025.

Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo
Analysis

Radiopharm Theranostics Ltd (RADX) Cost of Revenue (2024 - 2026) Analysis & Trends

Radiopharm Theranostics (RADX) has reported Cost of Revenue for 3 consecutive years, with $335000.6 the latest figure, recorded in Q2 2026.

Peer Set

Peer Comparison

All peers
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 335,000.61
Jun 30, 2025 3.59 Mn
Jun 30, 2024 213,252.42